Dyadic International (NASDAQ:DYAI) Stock Price Crosses Below 50-Day Moving Average – What’s Next?

Shares of Dyadic International Inc. (NASDAQ:DYAI) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.85 and traded as low as $0.7850. Dyadic International shares last traded at $0.8010, with a volume of 22,680 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dyadic International has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Trading Down 3.5%

The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.85 and a current ratio of 2.85. The company has a market capitalization of $28.99 million, a PE ratio of -3.34 and a beta of 1.29. The stock has a fifty day moving average of $0.85 and a 200 day moving average of $0.95.

Hedge Funds Weigh In On Dyadic International

A number of hedge funds and other institutional investors have recently modified their holdings of DYAI. Marathon Capital Management purchased a new position in Dyadic International during the third quarter valued at $41,000. Bank of America Corp DE lifted its stake in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. AlphaCore Capital LLC bought a new position in shares of Dyadic International during the 2nd quarter valued at about $50,000. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International during the third quarter valued at about $190,000. Finally, Geode Capital Management LLC grew its position in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.